2seventy bio Announces Upcoming Investor Events
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 13, 2021--
2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy.
- Session One: An Introduction to 2seventy’s Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy
- September 21, 2021, 11:00am-12:00pm ET
- Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy
- September 22, 2021, 1:00-2:00pm ET
To access the live webcasts and dial-in information for 2seventy bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210913005440/en/
CONTACT: Investors & Media
Elizabeth Pingpank, 617-914-8736
Jenn Snyder, 617-448-0281
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA CANADA
INDUSTRY KEYWORD: RESEARCH FDA GENETICS BIOTECHNOLOGY HEALTH GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY
SOURCE: bluebird bio
Copyright Business Wire 2021.
PUB: 09/13/2021 08:00 AM/DISC: 09/13/2021 08:06 AM